Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04963153
Title	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	urethra transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma ureter transitional cell carcinoma
Therapies	Enfortumab vedotin-ejfv + Erdafitinib
Age Groups:	adult \| senior
Covered Countries	USA \| CAN